ABMD Stock Price
ABMD RSI Chart
ABMD Valuation
ABMD Price/Sales (Trailing)
ABMD Profitability
ABMD Fundamentals
ABMD Revenue
ABMD Earnings
Price Action
Last 7 days
0.2%
Last 30 days
1.2%
Last 90 days
54.1%
Trailing 12 Months
14.7%
ABMD Financial Health
ABMD Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ABMD
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2022-02-17 | Rolle Myron L | sold (taxes) | -36,447 | 325 | -112 | - |
2022-02-17 | SUTTER MARTIN P | sold | -1,258,850 | 314 | -4,000 | - |
2022-02-16 | SUTTER MARTIN P | sold | -617,322 | 308 | -2,000 | - |
2022-02-16 | Weber David M | sold | -2,437,500 | 325 | -7,500 | chief operating officer |
2022-02-15 | SUTTER MARTIN P | sold | -607,301 | 303 | -2,000 | - |
2022-02-09 | Weber David M | acquired | 67,063 | 21.55 | 3,112 | chief operating officer |
2022-02-09 | Weber David M | sold | -965,311 | 310 | -3,112 | chief operating officer |
2022-02-08 | Weber David M | acquired | 159,750 | 21.55 | 7,413 | chief operating officer |
2022-02-08 | Weber David M | sold | -2,245,420 | 302 | -7,413 | chief operating officer |
2022-02-07 | Weber David M | acquired | 6,465 | 21.55 | 300 | chief operating officer |
Which funds bought or sold ABMD recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | sold off | -100 | -1,501,000 | - | -% |
2023-08-11 | HUNTINGTON NATIONAL BANK | unchanged | - | - | 381 | -% |
2023-03-17 | American Portfolios Advisors | reduced | -10.72 | -21,822 | 169,751 | 0.01% |
2023-02-13 | SEEYOND | sold off | -100 | -954,000 | - | -% |
2023-02-13 | HERITAGE WEALTH MANAGEMENT, LLC | sold off | -100 | -10,000 | - | -% |
2023-02-06 | Brinker Capital Investments, LLC | sold off | -100 | -2,066,000 | - | -% |
2023-01-24 | Autus Asset Management, LLC | sold off | -100 | -3,702,000 | - | -% |
2022-11-21 | 17 CAPITAL PARTNERS, LLC | unchanged | - | -2,000 | 281,000 | 0.38% |
2022-11-21 | FourThought Financial, LLC | reduced | -6.88 | -6,000 | 73,000 | 0.01% |
2022-11-15 | Covington Capital Management | new | - | 1,000 | 1,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Abiomed
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jan 06, 2023 | baillie gifford & co | 0.01% | 2,991 | SC 13G/A | |
| Dec 29, 2022 | millennium management llc | 0.0% | 0 | SC 13G | |
| Feb 09, 2022 | vanguard group inc | 10.64% | 4,842,984 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 5.41% | 2,461,221 | SC 13G | |
| Jan 18, 2022 | baillie gifford & co | 8.44% | 3,839,980 | SC 13G/A | |
| Jan 10, 2022 | blackrock inc. | 10.1% | 4,592,566 | SC 13G/A | |
| Feb 16, 2021 | sands capital management, llc | 3.27% | 1,479,909 | SC 13G | |
| Feb 10, 2021 | renaissance technologies llc | 4.41% | 1,993,800 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.63% | 4,801,759 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 9.1% | 4,127,359 | SC 13G/A |
Peers (Alternatives to Abiomed)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 109.7B | 19.5B | 4.61% | 32.58% | 40.5 | 5.64 | 10.36% | 30.30% |
ISRG | 102.6B | 6.7B | 1.85% | 46.31% | 71.98 | 15.39 | 11.75% | -0.66% |
BSX | 78.2B | 13.4B | 7.30% | 33.81% | 85.79 | 5.84 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -3.08% | 10.26% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 43.7B | 5.7B | -5.74% | -17.48% | 31.48 | 7.73 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 10.1B | 937.8M | 5.52% | 36.72% | 345.25 | 10.72 | 16.30% | 250.21% |
SWAV | 7.5B | 616.6M | -7.14% | -29.65% | 30.68 | 12.13 | 69.52% | 343.68% |
GMED | 5.3B | 1.1B | -4.57% | -12.56% | 25.23 | 4.84 | 12.63% | 50.85% |
IRTC | 2.7B | 452.1M | -16.85% | -42.51% | -27.51 | 6.04 | 24.99% | 24.09% |
TNDM | 1.5B | 790.3M | -18.06% | -57.30% | -6.6 | 1.87 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 421.8M | -8.54% | 49.60% | -9.62 | 3.81 | 44.49% | -2.43% |
AVNS | 952.1M | 780.7M | -7.00% | -11.88% | -26.45 | 1.22 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 620.2M | 162.9M | -26.12% | -63.06% | -11.73 | 3.81 | 42.67% | 12.82% |
Abiomed News
Returns for ABMD
Cumulative Returns on ABMD
39.5%
10-Year Cumulative Returns
23.2%
7-Year Cumulative Returns
14.7%
5-Year Cumulative Returns
32.7%
3-Year Cumulative Returns
Risks for ABMD
What is the probability of a big loss on ABMD?
80%
Probability that Abiomed stock will be more than 20% underwater in next one year
58.1%
Probability that Abiomed stock will be more than 30% underwater in next one year.
31.5%
Probability that Abiomed stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ABMD drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Abiomed was unfortunately bought at previous high price.
Drawdowns
Financials for Abiomed
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
| Revenue | 1.7% | 1,074 | 1,056 | 1,032 | 1,003 | 974 | 935 | 848 | 813 | 803 | 798 | 841 | 841 | 820 | 797 | 769 | 737 | 690 | 641 | 594 | 544 | 505 |
| Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99.00 | 88.00 | 82.00 |
| Costs and Expenses | 2.5% | 820 | 800 | 891 | 865 | 828 | 789 | 618 | 588 | 579 | 576 | 592 | 585 | 572 | 558 | 545 | 530 | 501 | 470 | 437 | 405 | 385 |
| S&GA Expenses | 3.2% | 452 | 438 | 423 | 414 | 393 | 369 | 334 | 318 | 317 | 324 | 342 | 339 | 334 | 326 | 322 | 316 | 302 | 283 | 263 | 247 | 235 |
| R&D Expenses | 0.6% | 167 | 166 | 163 | 152 | 144 | 133 | 122 | 115 | 108 | 101 | 99.00 | 99.00 | 97.00 | 96.00 | 94.00 | 89.00 | 83.00 | 80.00 | 75.00 | 70.00 | 69.00 |
| EBITDA | 23.9% | 369 | 298 | 219 | 217 | 239 | 243 | 313 | 278 | 293 | 237 | 278 | 335 | 301 | - | - | - | - | - | - | - | - |
| EBITDA Margin | 21.9% | 0.34* | 0.28* | 0.21* | 0.22* | 0.25* | 0.26* | 0.37* | 0.34* | 0.37* | 0.30* | 0.33* | 0.40* | 0.37* | - | - | - | - | - | - | - | - |
| Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 1.00 |
| Earnings Before Taxes | 26.5% | 341 | 270 | 191 | 189 | 212 | 218 | 288 | 254 | 270 | 215 | 257 | 316 | 284 | 318 | 263 | 213 | 194 | 175 | 160 | 141 | 121 |
| EBT Margin | 24.4% | 0.32* | 0.26* | 0.18* | 0.19* | 0.22* | 0.23* | 0.34* | 0.31* | 0.34* | 0.27* | 0.31* | 0.38* | 0.35* | - | - | - | - | - | - | - | - |
| Net Income | 22.6% | 267 | 218 | 137 | 133 | 149 | 154 | 226 | 200 | 208 | 159 | 203 | 245 | 221 | 258 | 259 | 222 | 190 | 165 | 112 | 90.00 | 92.00 |
| Net Income Margin | 20.6% | 0.25* | 0.21* | 0.13* | 0.13* | 0.15* | 0.17* | 0.27* | 0.25* | 0.26* | 0.20* | 0.24* | 0.29* | 0.27* | - | - | - | - | - | - | - | - |
| Free Cashflow | -17.3% | 217 | 263 | 250 | 246 | 233 | 248 | 221 | 237 | 246 | 240 | 271 | 257 | 243 | - | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
| Assets | -0.4% | 1,697 | 1,704 | 1,673 | 1,593 | 1,530 | 1,458 | 1,494 | 1,428 | 1,328 | 1,250 | 1,216 | 1,197 | 1,124 | 1,125 | 1,054 | 957 | 887 | 812 | 786 | 720 | 695 |
| Current Assets | 0.2% | 1,063 | 1,060 | 976 | 885 | 871 | 730 | 788 | 694 | 717 | 620 | 636 | 637 | 647 | 677 | 677 | 629 | 562 | 497 | 494 | 422 | 370 |
| Cash Equivalents | 1.0% | 182 | 180 | 133 | 144 | 242 | 175 | 233 | 181 | 202 | 215 | 192 | 118 | 150 | 101 | 121 | 84.00 | 76.00 | 61.00 | 43.00 | 51.00 | 45.00 |
| Inventory | 7.2% | 102 | 95.00 | 94.00 | 90.00 | 86.00 | 84.00 | 81.00 | 82.00 | 83.00 | 89.00 | 90.00 | 91.00 | 90.00 | 88.00 | 81.00 | 72.00 | 64.00 | 56.00 | 50.00 | 47.00 | 41.00 |
| Net PPE | -1.7% | 195 | 198 | 202 | 197 | 197 | 198 | 197 | 179 | 176 | 170 | 165 | 162 | 158 | 152 | 145 | 138 | 134 | 127 | 117 | 108 | 98.00 |
| Goodwill | -2.5% | 73.00 | 75.00 | 77.00 | 77.00 | 78.00 | 79.00 | 79.00 | 80.00 | 78.00 | 77.00 | 32.00 | 33.00 | 32.00 | 33.00 | 33.00 | 33.00 | 34.00 | 34.00 | 36.00 | 35.00 | 34.00 |
| Liabilities | -6.4% | 157 | 167 | 170 | 160 | 145 | 151 | 165 | 167 | 146 | 148 | 151 | 150 | 133 | 122 | 117 | 106 | 94.00 | 89.00 | 97.00 | 87.00 | 90.00 |
| Current Liabilities | -4.8% | 134 | 141 | 138 | 127 | 114 | 113 | 129 | 120 | 105 | 110 | 132 | 126 | 112 | 100 | 106 | 93.00 | 82.00 | 77.00 | 85.00 | 75.00 | 63.00 |
| Shareholder's Equity | 0.2% | 1,540 | 1,536 | 1,503 | 1,433 | 1,385 | 1,308 | 1,330 | 1,261 | 1,182 | 1,102 | 1,065 | 1,047 | 991 | 1,003 | 937 | 852 | 793 | 723 | 690 | 632 | 605 |
| Retained Earnings | 10.4% | 1,125 | 1,019 | 965 | 904 | 858 | 801 | 828 | 771 | 709 | 647 | 602 | 571 | 501 | 488 | 399 | 326 | 281 | 231 | 140 | 104 | 90.00 |
| Additional Paid-In Capital | 2.2% | 905 | 885 | 870 | 853 | 840 | 815 | 801 | 782 | 768 | 749 | 739 | 733 | 722 | 705 | 691 | 676 | 660 | 638 | 620 | 606 | 592 |
| Shares Outstanding | -0.9% | 45.00 | 46.00 | 46.00 | 46.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 45.00 | 44.00 | 44.00 | 44.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
| Cashflow From Operations | -15.8% | 251 | 298 | 285 | 293 | 282 | 298 | 275 | 275 | 285 | 282 | 315 | 299 | 284 | 270 | 252 | 238 | 220 | 203 | 193 | 173 | 151 |
| Share Based Compensation | 0.5% | 54.00 | 53.00 | 53.00 | 54.00 | 55.00 | 50.00 | 47.00 | 36.00 | 34.00 | 36.00 | 40.00 | 48.00 | 53.00 | 55.00 | 54.00 | 55.00 | 51.00 | 44.00 | 40.00 | 38.00 | 33.00 |
| Cashflow From Investing | 38.2% | -162 | -263 | -380 | -324 | -250 | -346 | -223 | -177 | -168 | -65.76 | -125 | -171 | -139 | -197 | -116 | -149 | -135 | -128 | -180 | -181 | -158 |
| Cashflow From Financing | -626.0% | -135 | -18.67 | -2.20 | -1.58 | 6.00 | 5.00 | -8.07 | -35.20 | -61.42 | -98.60 | -117 | -92.93 | -69.10 | -33.25 | -55.77 | -56.24 | -53.52 | -56.50 | -9.14 | -1.29 | 0.00 |
| Buy Backs | 772.2% | 253 | 29.00 | - | - | - | - | 11.00 | 36.00 | 61.00 | 96.00 | 85.00 | 120 | 139 | - | - | - | - | - | - | - | - |
ABMD Income Statement
2022-09-30Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
| Income Statement [Abstract] | ||||
| Revenue | $ 265,921 | $ 248,142 | $ 543,070 | $ 500,727 |
| Costs and expenses: | ||||
| Cost of revenue | 48,880 | 43,886 | 101,506 | 89,074 |
| Research and development | 42,089 | 41,041 | 82,566 | 78,749 |
| Selling, general and administrative | 116,958 | 102,779 | 234,954 | 206,263 |
| Acquired in-process research and development | 0 | 0 | 0 | 115,490 |
| Costs and Expenses, Total | 207,927 | 187,706 | 419,026 | 489,576 |
| Other (loss) income: | ||||
| Income from operations | 57,994 | 60,436 | 124,044 | 11,151 |
| Interest and other income, net | 80,709 | 6,835 | 84,481 | 46,770 |
| Income before income taxes | 138,703 | 67,271 | 208,525 | 57,921 |
| Income tax provision | 32,570 | 10,318 | 47,838 | 27,493 |
| Net income | $ 106,133 | $ 56,953 | $ 160,687 | $ 30,428 |
| Net income per share - basic | $ 2.34 | $ 1.25 | $ 3.53 | $ 0.67 |
| Weighted average shares outstanding - basic | 45,372 | 45,437 | 45,475 | 45,374 |
| Net income per share - diluted | $ 2.32 | $ 1.24 | $ 3.51 | $ 0.66 |
| Weighted average shares outstanding - diluted | 45,711 | 45,893 | 45,812 | 45,857 |
ABMD Balance Sheet
2022-09-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Mar. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 182,335 | $ 132,818 |
| Short-term marketable securities | 638,037 | 625,789 |
| Accounts receivable, net | 94,475 | 90,608 |
| Inventories, net | 102,237 | 93,981 |
| Prepaid expenses and other current assets | 45,714 | 33,277 |
| Total current assets | 1,062,798 | 976,473 |
| Long-term marketable securities | 116,871 | 220,089 |
| Property and equipment, net | 195,157 | 202,490 |
| Goodwill | 72,960 | 76,786 |
| Other intangibles, net | 36,833 | 39,518 |
| Deferred tax assets | 18,881 | 10,552 |
| Other assets | 193,044 | 147,485 |
| Total assets | 1,696,544 | 1,673,393 |
| Current liabilities: | ||
| Accounts payable | 35,070 | 35,346 |
| Accrued expenses | 69,434 | 72,629 |
| Deferred revenue | 25,962 | 26,362 |
| Other current liabilities | 3,594 | 4,120 |
| Total current liabilities | 134,060 | 138,457 |
| Other long-term liabilities | 7,013 | 9,319 |
| Contingent consideration | 14,995 | 21,510 |
| Deferred tax liabilities | 689 | 781 |
| Total liabilities | 156,757 | 170,067 |
| Commitments and contingencies (Note 16) | ||
| Stockholders' equity: | ||
| Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none | ||
| Common stock, $.01 par value 100,000 shares authorized; 48,418 and 48,258 shares issued as of September 31, 2022 and March 31, 2022, respectively 45,172 and 45,545 shares outstanding as of September 30, 2022 and March 31, 2022, respectively | 452 | 455 |
| Additional paid in capital | 904,755 | 870,074 |
| Retained earnings | 1,125,199 | 964,512 |
| Treasury stock at cost - 3,246 and 2,713 shares as of September 31, 2022 and March 31, 2022, respectively | (443,974) | (304,555) |
| Accumulated other comprehensive loss | (46,645) | (27,160) |
| Total stockholders' equity | 1,539,787 | 1,503,326 |
| Total liabilities and stockholders' equity | $ 1,696,544 | $ 1,673,393 |
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.